NOV 16, 2015 2:18 PM PST

Harnessing the Power of NK Cells to Fight Cancer

WRITTEN BY: Kara Marker
In the fight against cancer, immunotherapy is increasingly becoming a promising treatment option since it revolves around helping the body enhance its natural cancer-killing abilities. This week, scientists from the Institut de Recherches Cliniques de Montreal (IRCM) have discovered a new target for antibodies in immunotherapy development. 

Natural killer (NK) cells are lymphocytes that specialize in killing cancer cells. However, sometimes the action of NK cells is not enough to prevent the progression of cancer in the body. The group from IRCM looked to identify the mechanism behind the anti-cancer NK cell behavior with the idea of harnessing this action for use in immunotherapies. As described in their recent paper published in the Journal of Experimental Medicine, they finally discovered how an NK cell surface protein, DNAM-1, provided the stimulation behind the lymphocyte's cancer-killing tendencies. 
Various NK cell surface proteins

DNAM-1 competes with other surface receptors that might impede the cancer-killing action of NK cells. For example, the TIGIT receptor reduces NK cell efficiency. 

"When the TIGIT receptor interacts with an infected cell, it prevents its interaction with the DNAM-1 protein, which, as a result, suppresses the function of NK cells and slows the immune system," explained Dr. Andrew Veillette, leader of the IRCM study. 

As a cancer immunotherapy target, scientists could harness the action of DNAM-1 in the form of anti-TIGIT antibodies and other receptor blockers to enhance the natural cancer-fighting function of DNAM-1.

"This type of therapy could have a significant impact on the next generation of cancer treatments."

Watch the following video to learn more about different targets in the realm of cancer immunotherapy.
 
Source: IRCM
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 11, 2020
Immunology
Study Reveals the Two Sides of an Immune Molecule
AUG 11, 2020
Study Reveals the Two Sides of an Immune Molecule
Scientists have discovered a key protein that regulates the immune system to fight off infections. Fascinatingly, the pr ...
SEP 02, 2020
Immunology
Alarmins: The Immune "Gold" in Breast Milk
SEP 02, 2020
Alarmins: The Immune "Gold" in Breast Milk
We know that infants fed with breast milk develop more robust immune systems as a result of factors that support the nat ...
SEP 21, 2020
Cell & Molecular Biology
The Hormones We Have at Birth Are Linked to Disease Throughout Life
SEP 21, 2020
The Hormones We Have at Birth Are Linked to Disease Throughout Life
New work may help explain why some autoimmune or immune-related diseases are more common in women, who are more likely t ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
OCT 01, 2020
Immunology
Immune Cells and MS: The Good, the Bad, and the Maybe
OCT 01, 2020
Immune Cells and MS: The Good, the Bad, and the Maybe
Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a sim ...
NOV 09, 2020
Drug Discovery & Development
COVID-19 Vaccine by Pfizer More than 90% Effective
NOV 09, 2020
COVID-19 Vaccine by Pfizer More than 90% Effective
A preliminary analysis of Pfizer and BioNTech's COVID-19 vaccine shows that it can prevent over 90% of people from c ...
Loading Comments...